Clinical Evaluation of a New Oral Nonmercurial Diuretic

The oral administration of the organomercurial drugs in patients requiring prolonged management of congestive failure has been rather unsatisfactory because of occasional toxic signs and symptoms. With the development of the pyrimidinedione derivatives as diuretic agents and encouraging pharmacologic studies in animals, clinical trial is warranted. A group of 24 patients who had received injections of mercurial diuretics for at least 6 months prior to study were treated with this new diuretic. Results of this experience are described.